Why is "Idose" trending?
Latest news, Wikipedia summary, and trend analysis.
Trend Analysis
- Ranking position: #
- Date: 2026-07-21 11:15:34
This topic has appeared in the trending rankings 1 time(s) in the past year. While it does not trend frequently, its appearance suggests a renewed or concentrated surge of public interest.
Based on Wikipedia pageviews and search interest, this topic gained significant attention on the selected date.
Trend Insight
Idose entered the ranking for the first time today at position #. This is its highest position ever recorded.
Trend History
This topic has appeared in the English Wikipedia rankings 1 time. It first appeared on 2026-07-21 and was most recently seen on 2026-07-21.
Wikipedia Overview
Idose is a hexose, a six carbon monosaccharide. It has an aldehyde group and is thus an aldose. Idose is not found in nature, but its oxidized derivative iduronic acid, is a component of dermatan sulfate and heparan sulfate, which are glycosaminoglycans. The first and third hydroxyls point the opposite way from the second and fourth. It is made by aldol condensation of D- and L-glyceraldehyde. L-Idose is a C-5 epimer of D-glucose.
Read more on Wikipedia →Related Topics
Trending Topic Today
Search Interest Perspective
-
FDA approves NDA labeling supplement allowing re-administration of iDose TR - Ophthalmology Times Europe
-
Stifel raises Glaukos stock price target to $175 on iDose outlook - Investing.com
-
FDA Approves Labeling Update for iDose TR for Open-Angle Glaucoma and Ocular Hypertension - HCP Live
-
Glaukos gets FDA nod for iDose TR re-administration - Drug Delivery Business
-
FDA approves Glaukos' iDose TR for repeat treatment labeling - Eyes On Eyecare
-
New restriction on glaucoma care deserves closer look - Healio
-
Glaukos Announces US FDA Approval of NDA Supplement Allowing for Re-Administration of iDose® TR - Business Wire
-
How Investors May Respond To Glaukos (GKOS) FDA-Backed Repeat Protocol For iDose TR Implant - Yahoo Finance
-
Glaukos (GKOS) Piper Sandler 36th Annual Healthcare Conference Summary - Quartr
-
AAO 2025: 12-month outcomes of travoprost intracameral implant (iDose TR) in conjunction with cataract surgery - Ophthalmology Times Europe
-
Glaukos (GKOS) Stephens Annual Investment Conference Summary - Quartr
-
Surgical Considerations for Implanting Travoprost Intracameral Implant (iDose) - Ophthalmology Times Europe
-
Piper Sandler reiterates Glaukos stock rating on iDose headwinds - Investing.com
-
FDA approves repeat treatment protocol for Glaukos’ iDose TR - Investing.com
-
Glaukos (GKOS) Faces Selling Pressure Amid iDose Procedure Conce - GuruFocus
-
GKOS: iDose and Epioxa show strong growth amid evolving reimbursement and regulatory landscapes - TradingView
-
Here's Why You Should Retain Glaukos Stock in Your Portfolio Now - TradingView
-
Glaukos stock rises on FDA approval for iDose TR re-administration - Investing.com Nigeria
-
Glaukos (GKOS) Q1 2026 earnings summary - Quartr
-
A deeper look at the iDose from Glaukos | Eye Care Network - Ophthalmology Times Europe
-
Glaukos Announces Positive Clinical Updates for its iDose® Sustained-Release Procedural Pharmaceutical Platform - BioSpace
-
Glaukos Ramps Up iDose TR, Battles Legacy and Reimbursement Risks - Yahoo Finance
-
Glaukos reports positive IOP-lowering clinical data on iDose platform - Eyes On Eyecare
-
iDose TR shows sustained IOP reduction at 36 months in new analysis - Healio
-
FDA approves Glaukos iDose TR glaucoma-treating drug delivery implant - Drug Delivery Business
-
Sustained IOP Reduction With iDose TR, With Steven R. Sarkisian, Jr., MD - HCP Live
-
J-Code for Glaukos' iDose TR takes effect - Eyes On Eyecare
-
Glaukos Launches Implantable Glaucoma Treatment - Managed Healthcare Executive
-
Glaukos' iDose TR implant assigned permanent J-code - Eyes On Eyecare
-
ASCRS 2023: Phase 3 trials of iDose TR, versus topical timolol - Ophthalmology Times Europe
-
FDA approves Glaukos' iDose TR intracameral implant - Eyes On Eyecare
-
Glaukos' iDose TR intracameral launches in the US - Eyes On Eyecare
-
New Sustained-release Implant Approved for IOP Lowering - Review of Optometry
-
Glaukos Receives Permanent J-Code for iDose TR - Eyewire+
-
VIDEO: iDose TR launches, receives permanent J-code - Healio
-
Next stop for glaucoma medications: sustained drug delivery - EyeWorld
-
Glaukos wins FDA approval for drug-releasing eye implant to treat glaucoma - MedTech Dive
-
EyeWorld Weekly, March 3, 2023 - EyeWorld
-
Big Things in Small Packages - Review of Optometry
-
Glaukos Submits NDA to FDA for iDose TR - Eyewire+
-
EyeWorld Weekly, December 15, 2023 - EyeWorld
-
FDA approves travoprost intracameral implant - Ophthalmology Times Europe
-
Glaukos Announces FDA Approval of iDose TR - VisionMonday.com
-
EyeWorld Weekly, September 23, 2022 - EyeWorld
-
VIDEO: Glaukos discusses recent study results with iDose TR, iStent infinite - Healio
-
Glaukos Prepares for New Product Launches - Orange County Business Journal
-
First-of-its-kind glaucoma treatment now being used in Massachusetts - WCVB
-
FDA approves Glaukos iDose TR glaucoma implant - insightnews.com.au
-
Philips Introduces iDose4 Premium Package - Imaging Technology News
-
i-Doser: Digital Crack or Crock? - CBS News
-
Digital drug peddlers target teens with iDoses - SMH.com.au
-
Glaukos Stock Surges 18% on Record Q1 Sales Beat and Raised 2026 Outlook as iDose TR Demand Soars - International Business Times Australia
Why This Topic Is Trending
This topic has recently gained attention due to increased public interest. Search activity and Wikipedia pageviews suggest growing global engagement.
Search Interest & Related Topics
Search interest data over the past 12 months indicates that this topic periodically attracts global attention. Sudden spikes often correlate with major news events, public statements, or geopolitical developments.